<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id><journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id><journal-title-group><journal-title>Frontiers in Psychiatry</journal-title></journal-title-group><issn pub-type="epub">1664-0640</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29670549</article-id><article-id pub-id-type="pmc">5893781</article-id><article-id pub-id-type="doi">10.3389/fpsyt.2018.00113</article-id><article-categories><subj-group subj-group-type="heading"><subject>Psychiatry</subject><subj-group><subject>Clinical Trial</subject></subj-group></subj-group></article-categories><title-group><article-title>Educational and Behavioral Counseling in a Methadone Maintenance Treatment Program in China: A Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Pulin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="https://frontiersin.org/people/u/518968"/></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Ranran</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yao</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Cheng</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Bingxi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xuebing</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jiaoyuan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xueqin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ke</surname><given-names>Juntao</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lou</surname><given-names>Jiao</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Beibei</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zou</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gong</surname><given-names>Yajie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhong</surname><given-names>Rong</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Miao</surname><given-names>Xiaoping</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="fn001">*</xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Epidemiology and Biostatistics, Ministry of Education and Ministry of Environmental Protection, State Key Laboratory of Environmental Health (Incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology</institution>, <addr-line>Wuhan</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Wuhan Centers for Disease Prevention and Control</institution>, <addr-line>Wuhan</addr-line>, <country>China</country></aff><aff id="aff3"><sup>3</sup><institution>Wuhan Mental Health Center, Tongji Medical College, Huazhong University of Science and Technology</institution>, <addr-line>Wuhan</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Meichun Mohler-Kuo, University of Applied Sciences and Arts of Western Switzerland, Switzerland</p></fn><fn fn-type="edited-by"><p>Reviewed by: Leandro Da Costa Lane Valiengo, Universidade de S&#x000e3;o Paulo, Brazil; Maria Angeles Gomez Mart&#x000ed;nez, Pontifical University of Salamanca, Spain</p></fn><corresp id="fn001">*Correspondence: Xiaoping Miao, <email>miaoxp@hust.edu.cn</email></corresp><fn fn-type="other" id="fn002"><p>Specialty section: This article was submitted to Public Mental Health, a section of the journal Frontiers in Psychiatry</p></fn></author-notes><pub-date pub-type="epub"><day>04</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>113</elocation-id><history><date date-type="received"><day>27</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>19</day><month>3</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Liu, Song, Zhang, Liu, Cai, Liu, Li, Chen, Ke, Lou, Chen, Zhu, Zou, Yang, Zhu, Gong, Zhong and Miao.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Liu, Song, Zhang, Liu, Cai, Liu, Li, Chen, Ke, Lou, Chen, Zhu, Zou, Yang, Zhu, Gong, Zhong and Miao</copyright-holder><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract abstract-type="executive-summary"><sec id="ST1"><title>Introduction</title><p>Methadone maintenance treatment (MMT) programs have been rapidly scaled up nationwide in China in recent years, and psychosocial intervention measures, including counseling, were recommended for improving the outcomes of MMT. However, the effectiveness of counseling in MMT programs remains controversial. This study investigated the efficacy of educational and behavioral counseling (EBC) mode in an MMT program in China.</p></sec><sec id="ST2"><title>Methods</title><p>A total of 125 eligible participants were randomized to EBC or a control group. Patients in the EBC group received weekly, manual-guided, group educational counseling for 8&#x02009;weeks and individual behavioral counseling for the next 8&#x02009;weeks. Patients in the control group received standard methadone maintenance treatment as usual (TAU).</p></sec><sec id="ST3"><title>Results</title><p>During the 16-week trial, the EBC group showed better treatment attendance (<italic>P</italic>&#x02009;=&#x02009;0.022) and a greater increase in knowledge regarding heroin addiction (<italic>P</italic>&#x02009;=&#x02009;0.001) and MMT (<italic>P</italic>&#x02009;=&#x02009;0.005) than did the TAU group. Between the two groups, there were no significant differences regarding drug abstinence and reduction of risky behaviors.</p></sec><sec id="ST4"><title>Conclusion</title><p>EBC affiliated with MMT improved patients&#x02019; cognition and adherence to treatment, facilitating their successful recovery.</p></sec><sec id="ST5"><title>Clinical Trial Registration</title><p>ChiCTR-IOR-15006673: <uri xlink:type="simple" xlink:href="http://www.chictr.org.cn">http://www.chictr.org.cn</uri>.</p></sec></abstract><kwd-group><kwd>methadone maintenance treatment</kwd><kwd>counseling</kwd><kwd>psychosocial intervention</kwd><kwd>randomized controlled trial</kwd><kwd>China</kwd></kwd-group><funding-group><award-group><funding-source id="cn01">China Medical Board<named-content content-type="fundref-id">10.13039/100001547</named-content></funding-source><award-id rid="cn01">CMB09-991</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="5"/><equation-count count="0"/><ref-count count="34"/><page-count count="9"/><word-count count="6009"/></counts></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>China now has the world&#x02019;s largest number of illicit drugs users (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>), with this population representing a major driver of the country&#x02019;s HIV epidemic due to unsafe practices, such as sharing drug injection equipment (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). As an apparently effective harm reduction measure for reducing illicit opiate use, drug-related criminal behaviors and risk of HIV (<xref rid="B5" ref-type="bibr">5</xref>&#x02013;<xref rid="B7" ref-type="bibr">7</xref>), a national methadone maintenance treatment (MMT) program was initiated as an HIV control strategy in China in 2004 (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B8" ref-type="bibr">8</xref>). The program has seen a dramatic expansion from just 8 pilot clinics covering 1,029 clients in 2004 (<xref rid="B8" ref-type="bibr">8</xref>) to 763 clinics serving 412,686 total participants nationwide by the end of 2013 (<xref rid="B9" ref-type="bibr">9</xref>).</p><p>Despite the strong progress made in slowing the HIV infection rate among drug users in China, rapidly scaling up the MMT program has created a wide range of challenges and gaps that need to be addressed, such as the demand for qualified service providers, misconceptions regarding methadone medication, low average methadone doses, high rates of concurrent drug use among clients, high drop-out rates, and poor service quality in the clinics (<xref rid="B9" ref-type="bibr">9</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>). Hepatitis C infection among drug users is another serious public health problem that needs to be addressed in China (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B16" ref-type="bibr">16</xref>). A recent study of high rate of hepatitis C seroconversion in MMT programs also indicated an urgent need to improve MMT treatment services in order to obtain maximum benefits from this harm reduction approach (<xref rid="B17" ref-type="bibr">17</xref>).</p><p>Previous research in Western countries has demonstrated that the provision of additional counseling, medical, and psychosocial services produced dramatic enhancements to the efficacy of treatment with methadone medication alone and could improve the outcomes associated with MMT (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>). Conversely, there is also evidence that adding any psychosocial support to standard maintenance treatment does not add additional benefits (<xref rid="B18" ref-type="bibr">18</xref>).</p><p>China&#x02019;s national guidelines underline that comprehensive services, including behavioral interventions and psychological counseling, should play an important role in improving the efficacy of MMT programs (<xref rid="B9" ref-type="bibr">9</xref>). However, the guidelines do not provide a specific manual or existing model which can be applied to meet the psychosocial needs of MMT participants. Several previous randomized controlled trial researches in China has evaluated the availability and effectiveness of additional counseling or other psychosocial intervention measures, such as contingency management and cognitive behavioral therapy (<xref rid="B19" ref-type="bibr">19</xref>&#x02013;<xref rid="B22" ref-type="bibr">22</xref>), but most of these studies focused on individual level interventions for newly admitted patients in MMT clinics. In the context of MMT-related misconceptions among participants and insufficient human resources among MMT service providers in China (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>), a combination of group counseling with individual counseling could require a compromise between affordable psychosocial services from providers and the varied requirements of MMT participants.</p><p>In this study, we provided educational and behavioral counseling (EBC), including group and individual modes, directed at the characteristics of MMT patients. We hypothesized that EBC in addition to MMT would have greater efficacy compared to the current MMT in improving treatment attendance and reducing drug use. A 16-week randomized controlled trial was designed to evaluate the efficacy of EBC among MMT patients, and such outcomes as treatment attendance, drug abstinence, knowledge related to MMT and reduction of risky behaviors were investigated and assessed.</p></sec><sec sec-type="methods" id="S2"><title>Methods</title><sec id="S2-1"><title>Study Site and Participants</title><p>The study was conducted in Wuhan city, which is located in the central area of China and which initiated an MMT program in 2006. There were more than 20 MMT clinics serving over 13,000 opioid dependent patients in Wuhan. In consideration of the number of active patients, two of the largest MMT clinics affiliated with a mental health hospital were selected based on their convenience and willingness.</p><p>Study enrollment began in May 2012 and ended in July 2014. Candidate participants were recruited by the clinicians and the research assistant based on inclusion and exclusion criteria. Inclusion criteria were outpatients aged 18 to 65&#x02009;years, registered as local residents met the Chinese Classification of Mental Disorders 3 criteria for opioid dependence, had a positive urine test result for opioid at least once within the last month, and had no contra-indications for taking methadone. Exclusion criteria included being dependent on alcohol, benzodiazepines, or sedatives, and being psychotic, having major depression, or having other life-threatening or unstable medical problems. An interview was arranged by the clinic staff if a candidate participant expressed interest in the study, and a trained research assistant would make an initial face-to-face screening and explain the goals and procedures of the study to potential participants.</p></sec><sec id="S2-2"><title>Sample Size and Randomization</title><p>The proposed sample size was estimated based on an approximate simple formula (<xref rid="B25" ref-type="bibr">25</xref>). According to the literature (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B26" ref-type="bibr">26</xref>), treatment retention rate during study period in control groups was assumed to be 60&#x02013;65% and the detectable between-group difference was pre-estimated at 20&#x02013;25% after intervention. At a significance level of 0.05 (two-sided hypotheses) and power of 80%, we calculated that a minimum sample size of 54 subjects per group would be required. To compensate for participant drop-out, we decided to increase the target sample size to at least 60 subjects per group. A computer-generated randomization sequence assigned the eligible patients in a 1:1 ratio to the EBC or treatment as usual (TAU) group. Important variables, including gender, age, education, injection drug use, and years of MMT, were considered in order to ensure baseline comparability of the intervention group and control group.</p></sec><sec id="S2-3"><title>Assignment of Treatment</title><p>All patients in the clinics received methadone treatment according to the standard dosing protocols in the MMT programs in Wuhan. The initial dose of methadone was approximately 30&#x02013;40&#x02009;mg per day, and subsequently the methadone dose was increased by 10&#x02009;mg increments every 2&#x02009;days, and as long as there were no complaints of sedation or side effects, to a target dose of 60&#x02013;120&#x02009;mg daily. All doses were dispensed at the clinic under the direct observation of the clinic staff without take-home doses. All patients paid RMB <inline-graphic xlink:href="fpsyt-09-00113-i001.jpg"/>10 (USD $1.5) per dose regardless of the methadone volume, and in general, patients could consult doctors or nurses about their health concerns and clinics also offered some health education materials or gave an unscheduled educational lesson once a month or less.</p><p>Participants in the study were randomly allocated to receive one of the two treatments: the standard TAU or weekly EBC in addition to the standard treatment. All patients in the TAU group only received treatment services provided by clinic staff as usual. All participants in the EBC group received weekly EBC for 16 continuous weeks.</p><p>Educational and behavioral counseling intervention was made up of 16 counseling sessions (8 educational sessions and 8 behavioral sessions), and each session lasted for approximately 30&#x02013;45&#x02009;min. The educational sessions were conducted in a group of 3&#x02013;4 persons in the first 8&#x02009;weeks. These sessions included developing an understanding of opiate dependence as a chronic medical condition; the function of the methadone medication; the effect of heroin on the human body; the difficulty of opioids abstinence; the role of medication and counseling in the treatment process; basic knowledge of HIV/AIDS; as well as of HCV, HBV, and other blood-borne diseases; transmission and prevention of these diseases; and high-risk behaviors.</p><p>The behavioral sessions were conducted individually during the 9th&#x02013;16th weeks and focused on behavioral improvement including how to distinguish the triggers related to opiate dependence, how to cope with peer pressure, how to learn relapse prevention skills, how to establish and strengthen self-efficiency and training to avoid risk behaviors associated with injection drug use or sexual activity. Counselors emphasized the positive consequences of behavioral change (for instance, the benefits of not using drugs and of a healthy lifestyle) rather than the negative consequences or dangers of continuing drug use. Counselors acknowledged the patient&#x02019;s efforts and even their partial success at behavioral changes rather than focusing on the patient&#x02019;s failures to accomplish treatment goals.</p><p>All of the EBC sessions were manual-guided, and PowerPoint presentations were facilitated by a mixture of bachelor&#x02019;s- and master&#x02019;s-level counselors, who had minimal prior experiences in drug use counseling. All counselors initiated counseling after completing training in EBC, including a multiday didactic workshop, case conferences, and weekly supervised sessions.</p><p>During the 16-week study period, all participants were interviewed and asked to fill out questionnaires during the initial session and at every 4-week evaluation session. Every participant was offered RMB <inline-graphic xlink:href="fpsyt-09-00113-i001.jpg"/>30 (USD $4.5) for transportation vouchers to help to attend each scheduled assessment appointment.</p></sec><sec id="S2-4"><title>Outcome Measures</title><p>All participants&#x02019; baseline demographic characteristics and daily methadone medication doses were recorded by MMT clinicians who had been trained by our research assistants. Questionnaires on knowledge and substance use characteristics, which consisted of 39 multiple-choice and true/false questions, were administered at baseline and every 4&#x02009;weeks after study enrollment. These questionnaires were tested and adapted in MMT patients before the formal study. Illicit-drug use and opiate abstinence during treatment was measured by weekly urinalysis under supervision, using a semi-quantitative homogenous enzyme immunoassay for opioids with a cutoff set at 300&#x02009;ng/ml.</p><p>The primary outcome measures were defined before the study began and included treatment attendance and drug abstinence. Treatment attendance was defined as days of participants taking methadone treatment during the 16-week trial. Drug abstinence was defined as the number and percentage of opioid-negative urine specimens during the 16-week trial. These two primary outcomes were collected objectively from clinic medication records.</p><p>The secondary outcome measures included an improvement of scores on the knowledge of HIV/AIDS, heroin addiction and MMT, and reductions in risk behaviors which included the frequencies of drug injection, needles, or other injection equipment sharing. These secondary outcomes were collected from scheduled questionnaires and participant self-report.</p></sec><sec id="S2-5"><title>Data Analysis</title><p>Data from all randomized participants were included. All analyses were based on the intention-to-treat principle and performed by IBM SPSS Statistics 19.0. First, the participants&#x02019; sociodemographic indicators and clinical characteristics at enrollment were compared between the two groups with the use of the Chi-square test for categorical data, and independent-sample <italic>T</italic>-test or Mann&#x02013;Whitney <italic>U</italic> test were applied for continuous measures depending on the distribution. Second, the baseline characteristics were compared between participants who completed the study and participants who dropped out. Third, primary and secondary outcomes over time were evaluated between the EBC group and the TAU group, and generalized estimating equation (GEE) models were applied for further analysis. In the main outcomes analysis, group effects (EBC group versus TAU group) and time by group interactions were estimated. For continuous outcome variables (days of treatment attendance, knowledge scores), a linear GEE model was applied reporting unstandardized regression coefficients. For the categorical outcome variables (urine test result, risky behaviors), a binary or ordinal logistic GEE model was chosen reporting odds ratios. For all analyses, <italic>P</italic> values for two-tailed tests were reported. Significance level was set to 0.05.</p></sec></sec><sec id="S3"><title>Results</title><sec id="S3-1"><title>Recruitment of Participants</title><p>Two hundred three patients expressed interest in study participation. However, only 172 patients completed the screening process while 31 patients did not show up at the screening interview. During the screening process, 33 patients were excluded due to not meeting the inclusion criteria, and 14 patients had already been enrolled in other studies. In total, 125 patients were enrolled and randomized to the study treatment period. Study completion was defined as not missing medication for more than seven consecutive days or not missing three or more counseling sessions. Fourteen patients did not complete the entire study for various reasons, including being transferred to other cities (3 cases), being arrested (1 case), being lost to follow-up (4 cases), or withdrawal due to family or job issues (4 cases). There were also unknown reasons (2 cases). Finally, 56 patients from the intervention group and 55 patients from the control group completed the whole study. A flow diagram of the study is shown in Figure <xref ref-type="fig" rid="F1">1</xref>.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Enrollment and randomization.</p></caption><graphic xlink:href="fpsyt-09-00113-g001"/></fig></sec><sec id="S3-2"><title>Demographic and Clinical Characteristics</title><p>The baseline demographic and clinical characteristics of the patients enrolled are provided in Table <xref ref-type="table" rid="T1">1</xref>. The mean age of participants was 43.34&#x02009;years (SD: 6.88). Most of participants were male (74.4%), married (42.4%), unemployed (72.8%), and had less than a high school education (95.2%). The majority of participants injected drugs before enrollment and had detoxification experiences, 88.1 and 89.6%, respectively. The average dosage of methadone taken by participants during the study was 77.51&#x02009;mg/day (SD: 33.91). These characteristics did not differ significantly between the EBC and TAU participants.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of participants in educational and behavioral counseling (EBC) and treatment as usual (TAU) groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="center" rowspan="1" colspan="1">EBC (<italic>N</italic>&#x02009;=&#x02009;62)</th><th valign="top" align="center" rowspan="1" colspan="1">TAU (<italic>N</italic>&#x02009;=&#x02009;63)</th><th valign="top" align="center" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> or <italic>t</italic></th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender, <italic>n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.128</td><td align="center" valign="top" rowspan="1" colspan="1">0.721</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" valign="top" rowspan="1" colspan="1">47 (75.8)</td><td align="center" valign="top" rowspan="1" colspan="1">46 (73.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" valign="top" rowspan="1" colspan="1">15 (24.2)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (27.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education level, <italic>n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2.863</td><td align="center" valign="top" rowspan="1" colspan="1">0.413</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Primary school and less</td><td align="center" valign="top" rowspan="1" colspan="1">5 (8.1)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (6.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Junior middle school</td><td align="center" valign="top" rowspan="1" colspan="1">40 (64.5)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (57.1)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Senior high school</td><td align="center" valign="top" rowspan="1" colspan="1">13 (21.0)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (33.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;College or higher</td><td align="center" valign="top" rowspan="1" colspan="1">4 (6.4)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3.2)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marital status, <italic>n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.079</td><td align="center" valign="top" rowspan="1" colspan="1">0.898</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Unmarried</td><td align="center" valign="top" rowspan="1" colspan="1">17 (27.4)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (22.2)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Married</td><td align="center" valign="top" rowspan="1" colspan="1">26 (42.0)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (42.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;cohabitation</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;divorced</td><td align="center" valign="top" rowspan="1" colspan="1">16 (25.8)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (31.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Widowhood</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Employment, <italic>n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.121</td><td align="center" valign="top" rowspan="1" colspan="1">0.728</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">16 (25.8)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (28.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="top" rowspan="1" colspan="1">46 (74.2)</td><td align="center" valign="top" rowspan="1" colspan="1">45 (71.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Injection history, <italic>n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.216</td><td align="center" valign="top" rowspan="1" colspan="1">0.270</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">57 (91.9)</td><td align="center" valign="top" rowspan="1" colspan="1">54 (85.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="top" rowspan="1" colspan="1">5 (8.1)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (14.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Detoxification history, <italic>n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">2.058</td><td align="center" valign="top" rowspan="1" colspan="1">0.151</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">58 (93.5)</td><td align="center" valign="top" rowspan="1" colspan="1">54 (85.7)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="top" rowspan="1" colspan="1">4 (6.5)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (14.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">44.03 (7.44)</td><td align="center" valign="top" rowspan="1" colspan="1">42.65 (6.26)</td><td align="center" valign="top" rowspan="1" colspan="1">1.124</td><td align="center" valign="top" rowspan="1" colspan="1">0.263</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Drug use years, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">17.03 (4.70)</td><td align="center" valign="top" rowspan="1" colspan="1">15.35 (5.49)</td><td align="center" valign="top" rowspan="1" colspan="1">1.840</td><td align="center" valign="top" rowspan="1" colspan="1">0.068</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment years, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">5.19 (1.85)</td><td align="center" valign="top" rowspan="1" colspan="1">4.63 (1.85)</td><td align="center" valign="top" rowspan="1" colspan="1">1.682</td><td align="center" valign="top" rowspan="1" colspan="1">0.094</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Methadone dosage (mg/day), mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">75.87 (36.01)</td><td align="center" valign="top" rowspan="1" colspan="1">80.05 (33.89)</td><td align="center" valign="top" rowspan="1" colspan="1">0.688</td><td align="center" valign="top" rowspan="1" colspan="1">0.505</td></tr></tbody></table></table-wrap><p>There were no significant differences on gender, education, the history of injection and detoxification, years of MMT, and methadone dosage comparing the patients who dropped out (14 cases) to patients who completed the study (111 cases). There were significant differences between these two groups in age, employment, and marital status (Table <xref ref-type="table" rid="T2">2</xref>), indicating that young, unmarried, and unemployed patients were more likely to be unwilling to complete the study. The proportion of patients who had completed the study did not differ significantly between the EBC group (90.32%) and the TAU group (87.30%) (<italic>P</italic>&#x02009;=&#x02009;0.592).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Characteristics of participants and drop-outs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="center" rowspan="1" colspan="1">Participants (<italic>N</italic>&#x02009;=&#x02009;111)</th><th valign="top" align="center" rowspan="1" colspan="1">Drop-outs (<italic>N</italic>&#x02009;=&#x02009;14)</th><th valign="top" align="center" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> or <italic>t</italic></th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender, <italic>n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.073</td><td align="center" valign="top" rowspan="1" colspan="1">0.787</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" valign="top" rowspan="1" colspan="1">83 (74.8)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (71.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" valign="top" rowspan="1" colspan="1">28 (25.2)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (28.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education level, <italic>n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">5.615</td><td align="center" valign="top" rowspan="1" colspan="1">0.132</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Primary school and less</td><td align="center" valign="top" rowspan="1" colspan="1">6 (5.4)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (21.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Junior middle school</td><td align="center" valign="top" rowspan="1" colspan="1">68 (61.3)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (57.1)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Senior high school</td><td align="center" valign="top" rowspan="1" colspan="1">32 (28.8)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (14.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;College or higher</td><td align="center" valign="top" rowspan="1" colspan="1">5 (4.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (7.1)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marital status, <italic>n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">13.331</td><td align="center" valign="top" rowspan="1" colspan="1">0.010<xref ref-type="table-fn" rid="tfn1">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Unmarried</td><td align="center" valign="top" rowspan="1" colspan="1">22 (19.8)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (64.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Married</td><td align="center" valign="top" rowspan="1" colspan="1">50 (45.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (21.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;cohabitation</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;divorced</td><td align="center" valign="top" rowspan="1" colspan="1">34 (30.6)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (14.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Widowhood</td><td align="center" valign="top" rowspan="1" colspan="1">3 (2.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Employment, <italic>n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">5.891</td><td align="center" valign="top" rowspan="1" colspan="1">0.015<xref ref-type="table-fn" rid="tfn1">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">34 (30.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="top" rowspan="1" colspan="1">77 (69.4)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (100)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Injection history, <italic>n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.261</td><td align="center" valign="top" rowspan="1" colspan="1">0.609</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">98 (88.3)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (92.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="top" rowspan="1" colspan="1">13 (11.7)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (7.1)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Detoxification history, <italic>n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.179</td><td align="center" valign="top" rowspan="1" colspan="1">0.672</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">99 (89.2)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (92.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No</td><td align="center" valign="top" rowspan="1" colspan="1">12 (10.8)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (7.1)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">43.86 (6.61)</td><td align="center" valign="top" rowspan="1" colspan="1">39.14 (7.76)</td><td align="center" valign="top" rowspan="1" colspan="1">2.469</td><td align="center" valign="top" rowspan="1" colspan="1">0.015<xref ref-type="table-fn" rid="tfn1">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Drug use years, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">16.50 (5.141)</td><td align="center" valign="top" rowspan="1" colspan="1">13.71 (4.795)</td><td align="center" valign="top" rowspan="1" colspan="1">1.921</td><td align="center" valign="top" rowspan="1" colspan="1">0.057</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment years, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">4.96 (1.892)</td><td align="center" valign="top" rowspan="1" colspan="1">4.50 (1.653)</td><td align="center" valign="top" rowspan="1" colspan="1">0.876</td><td align="center" valign="top" rowspan="1" colspan="1">0.383</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Methadone dosage (mg/day), mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">78.04 (35.07)</td><td align="center" valign="top" rowspan="1" colspan="1">77.50 (34.54)</td><td align="center" valign="top" rowspan="1" colspan="1">0.054</td><td align="center" valign="top" rowspan="1" colspan="1">0.957</td></tr></tbody></table><table-wrap-foot><fn id="tfn1"><p><italic>*P&#x02009;&#x0003c;&#x02009;0.05</italic>.</p></fn></table-wrap-foot></table-wrap><p>An overview of the primary and secondary outcomes of the patients in the EBC and TAU groups was presented in Table <xref ref-type="table" rid="T3">3</xref>. The results showed no significant differences in the proportion of opiate-negative urine specimens (<italic>P</italic>&#x02009;=&#x02009;0.054), the proportion of patients who had no injection within the last month (<italic>P</italic>&#x02009;=&#x02009;0.816), and proportion who had no needle or other equipment sharing (<italic>P</italic>&#x02009;=&#x02009;0.986). Significant differences were found in treatment attendance (<italic>P</italic>&#x02009;=&#x02009;0.025), total knowledge scores, and subgroup scores of knowledge related to heroin addiction and MMT (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), which indicated that the EBC group had better performance on adherence to treatment and knowledge awareness improvement in general. Further statistical analysis of GEE models was implemented to control for drop-outs&#x02019; incomplete data and to correct within-subject correlations in repeated measurements.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Primary and secondary outcomes in educational and behavioral counseling (EBC) and treatment as usual (TAU) groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Outcomes</th><th valign="top" align="center" rowspan="1" colspan="1">EBC (<italic>N</italic>&#x02009;=&#x02009;62)</th><th valign="top" align="center" rowspan="1" colspan="1">TAU (<italic>N</italic>&#x02009;=&#x02009;63)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="4" rowspan="1"><bold>Primary outcomes</bold></td></tr><tr><td align="left" valign="top" colspan="4" rowspan="1">Treatment attendance-days</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Median</td><td align="center" valign="top" rowspan="1" colspan="1">91.00</td><td align="center" valign="top" rowspan="1" colspan="1">79.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.025<xref ref-type="table-fn" rid="tfn2">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;IQR</td><td align="center" valign="top" rowspan="1" colspan="1">73.75&#x02013;102.25</td><td align="center" valign="top" rowspan="1" colspan="1">47.00&#x02013;99.00</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" colspan="4" rowspan="1">Opiate-negative urine specimens-%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mean</td><td align="center" valign="top" rowspan="1" colspan="1">76.74</td><td align="center" valign="top" rowspan="1" colspan="1">67.38</td><td align="center" valign="top" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;95%CI</td><td align="center" valign="top" rowspan="1" colspan="1">70.75&#x02013;82.47</td><td align="center" valign="top" rowspan="1" colspan="1">60.11&#x02013;74.17</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" colspan="4" rowspan="1"><bold>Secondary outcomes</bold></td></tr><tr><td align="left" valign="top" colspan="4" rowspan="1">Total score of knowledge</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mean</td><td align="center" valign="top" rowspan="1" colspan="1">10.56</td><td align="center" valign="top" rowspan="1" colspan="1">8.94</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tfn3">**</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;95%CI</td><td align="center" valign="top" rowspan="1" colspan="1">10.25&#x02013;10.87</td><td align="center" valign="top" rowspan="1" colspan="1">8.61&#x02013;9.27</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" colspan="4" rowspan="1">Subscore 1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mean</td><td align="center" valign="top" rowspan="1" colspan="1">2.25</td><td align="center" valign="top" rowspan="1" colspan="1">1.16</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tfn3">**</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;95%CI</td><td align="center" valign="top" rowspan="1" colspan="1">2.11&#x02013;2.40</td><td align="center" valign="top" rowspan="1" colspan="1">1.03&#x02013;1.29</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" colspan="4" rowspan="1">Subscore 2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mean</td><td align="center" valign="top" rowspan="1" colspan="1">4.81</td><td align="center" valign="top" rowspan="1" colspan="1">4.24</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tfn3">**</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;95%CI</td><td align="center" valign="top" rowspan="1" colspan="1">4.66&#x02013;4.97</td><td align="center" valign="top" rowspan="1" colspan="1">4.03&#x02013;4.44</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" colspan="4" rowspan="1">Subscore 3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mean</td><td align="center" valign="top" rowspan="1" colspan="1">3.49</td><td align="center" valign="top" rowspan="1" colspan="1">3.55</td><td align="center" valign="top" rowspan="1" colspan="1">0.475</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;95%CI</td><td align="center" valign="top" rowspan="1" colspan="1">3.39&#x02013;3.60</td><td align="center" valign="top" rowspan="1" colspan="1">3.44&#x02013;3.65</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" colspan="4" rowspan="1">No Injection within last month-%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mean</td><td align="center" valign="top" rowspan="1" colspan="1">52.9</td><td align="center" valign="top" rowspan="1" colspan="1">57.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.816</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;95%CI</td><td align="center" valign="top" rowspan="1" colspan="1">47.1&#x02013;58.8</td><td align="center" valign="top" rowspan="1" colspan="1">51.2&#x02013;63.2</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" colspan="4" rowspan="1">Needles or other equipment Sharing-%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mean</td><td align="center" valign="top" rowspan="1" colspan="1">13.9</td><td align="center" valign="top" rowspan="1" colspan="1">13.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.986</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;95%CI</td><td align="center" valign="top" rowspan="1" colspan="1">9.9&#x02013;17.9</td><td align="center" valign="top" rowspan="1" colspan="1">9.3&#x02013;17.4</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p><italic>CI, confidence interval; IQR, inter-quartile range; Subscore1, score of knowledge related to heroin addiction; Subscore2, score of knowledge related to methadone maintenance treatment; Subscore3, score of knowledge related to HIV/AIDS</italic>.</p><fn id="tfn2"><p><italic>*P&#x02009;&#x0003c;&#x02009;0.05</italic>.</p></fn><fn id="tfn3"><p><italic>**P&#x02009;&#x0003c;&#x02009;0.01</italic>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="S3-3"><title>Generalized Estimating Equation Analysis</title><p>As shown in Table <xref ref-type="table" rid="T4">4</xref>, the GEE analyses found that there was a significant difference in treatment attendance between the EBC and the TAU group (<italic>P</italic>&#x02009;=&#x02009;0.022). However, the interaction effect of group and time was not significantly different (<italic>P</italic>&#x02009;=&#x02009;0.480). These results indicated that patients in the EBC group had better treatment attendance than those in TAU group and the group difference did not differ as the time of assessment differed, and the characteristics also were presented in Figure <xref ref-type="fig" rid="F2">2</xref>.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Generalized estimating equation analyses for primary and secondary outcomes (continuous variables).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Outcomes</th><th valign="top" align="left" rowspan="1" colspan="1">Group</th><th valign="top" align="center" colspan="5" rowspan="1">Estimated marginal means (SE)<hr/></th><th valign="top" align="center" rowspan="1" colspan="1">Group effect</th><th valign="top" align="center" rowspan="1" colspan="1">Time&#x02009;&#x000d7;&#x02009;group interaction</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">Week 0</th><th valign="top" align="center" rowspan="1" colspan="1">Week 1&#x02013;4</th><th valign="top" align="center" rowspan="1" colspan="1">Week 5&#x02013;8</th><th valign="top" align="center" rowspan="1" colspan="1">Week 9&#x02013;12</th><th valign="top" align="center" rowspan="1" colspan="1">Week 13&#x02013;16</th><th valign="top" align="center" rowspan="1" colspan="1">&#x003b2; (95%CI)</th><th valign="top" align="center" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment attendance</td><td align="left" valign="top" rowspan="1" colspan="1">EBC</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">20.11 (0.920)</td><td align="center" valign="top" rowspan="1" colspan="1">22.41 (0.718)</td><td align="center" valign="top" rowspan="1" colspan="1">22.25 (0.820)</td><td align="center" valign="top" rowspan="1" colspan="1">22.13 (0.833)</td><td align="center" valign="top" rowspan="1" colspan="1">3.089 (0.436&#x02013;5.741)</td><td align="center" valign="top" rowspan="1" colspan="1">wald&#x02009;=&#x02009;2.475, <italic>P</italic>&#x02009;=&#x02009;0.480</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">TAU</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">18.71 (0.905)</td><td align="center" valign="top" rowspan="1" colspan="1">19.72 (0.928)</td><td align="center" valign="top" rowspan="1" colspan="1">19.84 (1.032)</td><td align="center" valign="top" rowspan="1" colspan="1">19.04 (1.066)</td><td align="center" valign="top" rowspan="1" colspan="1">wald&#x02009;=&#x02009;5.208, <italic>P</italic>&#x02009;=&#x02009;0.022<xref ref-type="table-fn" rid="tfn4">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total scores</td><td align="left" valign="top" rowspan="1" colspan="1">EBC</td><td align="center" valign="top" rowspan="1" colspan="1">8.39 (0.302)</td><td align="center" valign="top" rowspan="1" colspan="1">10.75 (0.317)</td><td align="center" valign="top" rowspan="1" colspan="1">10.87 (0.298)</td><td align="center" valign="top" rowspan="1" colspan="1">11.26 (0.317)</td><td align="center" valign="top" rowspan="1" colspan="1">11.6 (0.331)</td><td align="center" valign="top" rowspan="1" colspan="1">2.294 (1.217&#x02013;3.371)</td><td align="center" valign="top" rowspan="1" colspan="1">wald&#x02009;=&#x02009;26.829, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001<xref ref-type="table-fn" rid="tfn5">**</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">TAU</td><td align="center" valign="top" rowspan="1" colspan="1">8.09 (0.328)</td><td align="center" valign="top" rowspan="1" colspan="1">8.84 (0.332)</td><td align="center" valign="top" rowspan="1" colspan="1">9.4 (0.312)</td><td align="center" valign="top" rowspan="1" colspan="1">9.18 (0.441)</td><td align="center" valign="top" rowspan="1" colspan="1">9.31 (0.438)</td><td align="center" valign="top" rowspan="1" colspan="1">wald&#x02009;=&#x02009;17.426, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001<xref ref-type="table-fn" rid="tfn5">**</xref></td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Subscore1</td><td align="left" valign="top" rowspan="1" colspan="1">EBC</td><td align="center" valign="top" rowspan="1" colspan="1">1.36 (0.135)</td><td align="center" valign="top" rowspan="1" colspan="1">2.46 (0.164)</td><td align="center" valign="top" rowspan="1" colspan="1">2.36 (0.144)</td><td align="center" valign="top" rowspan="1" colspan="1">2.42 (0.161)</td><td align="center" valign="top" rowspan="1" colspan="1">2.70 (0.161)</td><td align="center" valign="top" rowspan="1" colspan="1">1.341 (0.880&#x02013;1.802)</td><td align="center" valign="top" rowspan="1" colspan="1">wald&#x02009;=&#x02009;19.986, <italic>P</italic>&#x02009;=&#x02009;0.001<xref ref-type="table-fn" rid="tfn5">**</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">TAU</td><td align="center" valign="top" rowspan="1" colspan="1">0.85 (0.113)</td><td align="center" valign="top" rowspan="1" colspan="1">1.04 (0.126)</td><td align="center" valign="top" rowspan="1" colspan="1">1.27 (0.142)</td><td align="center" valign="top" rowspan="1" colspan="1">1.33 (0.170)</td><td align="center" valign="top" rowspan="1" colspan="1">1.36 (0.171)</td><td align="center" valign="top" rowspan="1" colspan="1">wald&#x02009;=&#x02009;19.986, <italic>P</italic>&#x02009;=&#x02009;0.001<xref ref-type="table-fn" rid="tfn5">**</xref></td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Subscore2</td><td align="left" valign="top" rowspan="1" colspan="1">EBC</td><td align="center" valign="top" rowspan="1" colspan="1">3.98 (0.195)</td><td align="center" valign="top" rowspan="1" colspan="1">4.79 (0.163)</td><td align="center" valign="top" rowspan="1" colspan="1">4.96 (0.143)</td><td align="center" valign="top" rowspan="1" colspan="1">5.21 (0.159)</td><td align="center" valign="top" rowspan="1" colspan="1">5.17 (0.170)</td><td align="center" valign="top" rowspan="1" colspan="1">0.884 (0.262&#x02013;1.506)</td><td align="center" valign="top" rowspan="1" colspan="1">wald&#x02009;=&#x02009;9.632, <italic>P</italic>&#x02009;=&#x02009;0.047<xref ref-type="table-fn" rid="tfn4">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">TAU</td><td align="center" valign="top" rowspan="1" colspan="1">3.89 (0.195)</td><td align="center" valign="top" rowspan="1" colspan="1">4.18 (0.230)</td><td align="center" valign="top" rowspan="1" colspan="1">4.51 (0.194)</td><td align="center" valign="top" rowspan="1" colspan="1">4.33 (0.254)</td><td align="center" valign="top" rowspan="1" colspan="1">4.29 (0.268)</td><td align="center" valign="top" rowspan="1" colspan="1">wald&#x02009;=&#x02009;7.758, <italic>P</italic>&#x02009;=&#x02009;0.005<xref ref-type="table-fn" rid="tfn5">**</xref></td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Subscore3</td><td align="left" valign="top" rowspan="1" colspan="1">EBC</td><td align="center" valign="top" rowspan="1" colspan="1">3.05 (0.135)</td><td align="center" valign="top" rowspan="1" colspan="1">3.50 (0.101)</td><td align="center" valign="top" rowspan="1" colspan="1">3.55 (0.113)</td><td align="center" valign="top" rowspan="1" colspan="1">3.64 (0.104)</td><td align="center" valign="top" rowspan="1" colspan="1">3.74 (0.100)</td><td align="center" valign="top" rowspan="1" colspan="1">0.069 (&#x02212;0.264 to 0.403)</td><td align="center" valign="top" rowspan="1" colspan="1">wald&#x02009;=&#x02009;5.738, <italic>P</italic>&#x02009;=&#x02009;0.220</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">TAU</td><td align="center" valign="top" rowspan="1" colspan="1">3.35 (0.132)</td><td align="center" valign="top" rowspan="1" colspan="1">3.62 (0.087)</td><td align="center" valign="top" rowspan="1" colspan="1">3.62 (0.101)</td><td align="center" valign="top" rowspan="1" colspan="1">3.51 (0.142)</td><td align="center" valign="top" rowspan="1" colspan="1">3.67 (0.137)</td><td align="center" valign="top" rowspan="1" colspan="1">wald&#x02009;=&#x02009;0.165, <italic>P</italic>&#x02009;=&#x02009;0.684</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p><italic>CI, confidence interval; TAU, treatment as usual; EBC, educational and behavioral counseling; Subscore1, score of knowledge related to heroin addiction; Subscore2, score of knowledge related to methadone maintenance treatment; Subscore3, score of knowledge related to HIV/AIDS</italic>.</p><fn id="tfn4"><p><italic>*P&#x02009;&#x0003c;&#x02009;0.05</italic>.</p></fn><fn id="tfn5"><p><italic>**P&#x02009;&#x0003c;&#x02009;0.01</italic>.</p></fn></table-wrap-foot></table-wrap><fig id="F2" position="float"><label>Figure 2</label><caption><p>Treatment attendance of educational and behavioral counseling (EBC) and treatment as usual (TAU) group. The patients in the EBC group showed better treatment attendance than those in TAU group. There was not significantly group different during weeks 9&#x02013;12 (*<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01).</p></caption><graphic xlink:href="fpsyt-09-00113-g002"/></fig><p>Regarding the total knowledge scores and knowledge subgroup scores related to heroin addiction and MMT, significant differences between the EBC and TAU group were found by the GEE analyses (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, <italic>P</italic>&#x02009;=&#x02009;0.001 and 0.005, respectively). There was also a significant interaction effect of group and time in these knowledge scores. These results demonstrated that EBC had a greater improvement on knowledge awareness than was seen in the TAU group, and this group difference became more apparent as the time of assessment differed (Figure <xref ref-type="fig" rid="F3">3</xref>). We did not identify a similar difference or time trend on the scores of knowledge related to HIV/AIDS between the EBC and the TAU group.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Knowledge scores of educational and behavioral counseling (EBC) and treatment as usual (TAU) group. <bold>(A&#x02013;C)</bold> presented significant differences between the EBC and TAU group on the total knowledge scores and knowledge subgroup scores related to heroin addiction and methadone maintenance treatment, and <bold>(D)</bold> showed that there is no significant difference between the EBC and TAU group on the knowledge subgroup scores related to HIV/AIDS (*<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01).</p></caption><graphic xlink:href="fpsyt-09-00113-g003"/></fig><p>We found no significant differences between the EBC and the TAU group in the outcomes of the urinalysis results and reduction of risky behaviors, including drug injection frequency and sharing needles with others within the last month (Table <xref ref-type="table" rid="T5">5</xref>). However, the interaction of group and time showed a significant difference in injection frequencies (<italic>P</italic>&#x02009;=&#x02009;0.015). This implied that drug abstinence and reduction of risky behaviors did not have group differences, but injection frequencies were reduced as the time of assessment differed in both groups.</p><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Generalized estimating equation analyses for primary and secondary outcomes (categorical variables).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Outcomes</th><th valign="top" align="left" rowspan="1" colspan="1">Group</th><th valign="top" align="center" rowspan="1" colspan="1">OR</th><th valign="top" align="center" colspan="2" rowspan="1">95%CI<hr/></th><th valign="top" align="center" colspan="2" rowspan="1">Group effect<hr/></th><th valign="top" align="center" colspan="2" rowspan="1">Time&#x02009;&#x000d7;&#x02009;group interaction<hr/></th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">Lower</th><th valign="top" align="center" rowspan="1" colspan="1">Upper</th><th valign="top" align="center" rowspan="1" colspan="1">Wald Chi-square</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th><th valign="top" align="center" rowspan="1" colspan="1">Wald Chi-square</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Urine analysis</td><td align="left" valign="top" rowspan="1" colspan="1">EBC</td><td align="center" valign="top" rowspan="1" colspan="1">0.423</td><td align="center" valign="top" rowspan="1" colspan="1">0.100</td><td align="center" valign="top" rowspan="1" colspan="1">1.791</td><td align="center" valign="top" rowspan="1" colspan="1">1.365</td><td align="center" valign="top" rowspan="1" colspan="1">0.243</td><td align="center" valign="top" rowspan="1" colspan="1">18.179</td><td align="center" valign="top" rowspan="1" colspan="1">0.253</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">TAU</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Injection frequency</td><td align="left" valign="top" rowspan="1" colspan="1">EBC</td><td align="center" valign="top" rowspan="1" colspan="1">0.725</td><td align="center" valign="top" rowspan="1" colspan="1">0.318</td><td align="center" valign="top" rowspan="1" colspan="1">1.652</td><td align="center" valign="top" rowspan="1" colspan="1">0.585</td><td align="center" valign="top" rowspan="1" colspan="1">0.444</td><td align="center" valign="top" rowspan="1" colspan="1">12.339</td><td align="center" valign="top" rowspan="1" colspan="1">0.015<xref ref-type="table-fn" rid="tfn6">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">TAU</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Needles Sharing or not</td><td align="left" valign="top" rowspan="1" colspan="1">EBC</td><td align="center" valign="top" rowspan="1" colspan="1">0.444</td><td align="center" valign="top" rowspan="1" colspan="1">0.100</td><td align="center" valign="top" rowspan="1" colspan="1">1.976</td><td align="center" valign="top" rowspan="1" colspan="1">1.136</td><td align="center" valign="top" rowspan="1" colspan="1">0.287</td><td align="center" valign="top" rowspan="1" colspan="1">7.431</td><td align="center" valign="top" rowspan="1" colspan="1">0.115</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">TAU</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p><italic>TAU, treatment as usual; EAU, educational and behavioral counseling</italic>.</p><fn id="tfn6"><p><italic>*P&#x02009;&#x0003c;&#x02009;0.05</italic>.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="S4"><title>Discussion</title><p>In this study, we evaluated the efficacy of an EBC model, including group educational counseling sessions and individual behavioral counseling sessions, in an MMT program in China with a randomized control trial design. We observed that outcomes among patients in the EBC group, such as treatment attendance and scores of knowledge related to heroin addiction and MMT, differed significantly from those of the TAU group. We also observed that no significant group differences in the study phase were reported in the outcomes of opioids-negative urinalysis and reduction of risky behaviors. The findings of our study indicated that EBC intervention could contribute to a better understanding of treatment goals and to the improvement of treatment adherence, which reinforces the goal of continuously benefiting from MMT for opioids dependence patients. Our study results also demonstrated that current behavioral counseling may not be sufficiently effective to bring more significant behavioral change compared to a medication-only regimen and implied that more efforts beyond counseling should be made to help these patients.</p><p>Our study results are in contrast with other researchers who have demonstrated encouraging results for improvement in treatment retention and reduction of opiate use with ancillary psychosocial services in MMT patients in China. One pilot study involving 37 MMT patients showed that counseling services led by nurse counselors were effective in reducing HIV risk behaviors and drug use (<xref rid="B19" ref-type="bibr">19</xref>). Another randomized controlled trial evaluated the efficacy of a psychosocial intervention that included individual and family based counseling among newly admitted first-time MMT patients and observed a significant reduction in attrition and improvement in days of attendance (<xref rid="B20" ref-type="bibr">20</xref>). It should be noted that 79.2% (99/125) of the participants in our study had taken MMT for more than 4&#x02009;years, and our findings demonstrate that the current EBC intervention has limited efficacy in these patients with many years of treatment. These findings cannot be simply interpreted to mean that methadone treatment is so efficacious that an EBC intervention adds little benefit and is not needed in the current MMT program at all. MMT providers in the participating clinics typically offer many additional services, such as regular communication on medication adherence, drug abstinence, and educational pamphlets, to all MMT patients (<xref rid="B27" ref-type="bibr">27</xref>). Many patients have benefited from these additional services and seen some successful progress after several years of medication treatment (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). For these patients, a low-intensity EBC intervention would not be beneficial and a much higher intensity psychosocial intervention measurement is likely needed (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Next steps include developing tailored strategies for matching the diverse intensities of MMT service with the specific needs of individual patients and providing referrals to high intensity interventions as needed (<xref rid="B32" ref-type="bibr">32</xref>).</p><p>Psychosocial services, including counseling, in MMT in China have not been thoroughly developed (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>), and our present study could provide several lessons that could be used to improve the quality of MMT. We developed systematic educational materials, including PowerPoint slides and a manual for 16 consecutive counseling sessions. We also set up a procedure for training counselors to provide high quality counseling for MMT patients. These efforts and experiences make it possible to train more nurses or other MMT service providers who lack an advanced background in psychology to provide an EBC service in more clinics.</p><p>Our study had some potential limitations. First, we did not conduct a follow-up investigation to explore the long-term effects of the EBC, which limits the generalizability of our findings. Second, patients who enrolled in our study were not evaluated for degree of addiction severity, and patients with more severe addiction might have a stronger motivation or determination for change than those who were not enrolled. These parameters could be important confounding factors for assessing the effectiveness of intervention, and we should be cautious in applying the results to the general patient population. Third, we could not make more frequent urine measurements, and assessment of the use of illegal drugs other than opioids might have provided more meaningful information (<xref rid="B34" ref-type="bibr">34</xref>).</p><p>In summary, the results of our study have demonstrated preliminary feasibility and viability of EBC affiliated with MMT in China, and EBC has been demonstrated to contribute to a better improvement in knowledge awareness and treatment attendance. More research aimed at developing tailored strategies for various intensities of EBC is needed in order to help patients maintain abstinence and reduce individual risk behaviors.</p></sec><sec id="S5"><title>Ethics Statement</title><p>The study protocol was approved by the Human Investigation Committee of Tongji Medical School, Huazhong University of Science and Technology. Informed and voluntary written consent was obtained from every participant who passed the screening. This study was registered at <uri xlink:type="simple" xlink:href="http://www.chictr.org.cn">http://www.chictr.org.cn</uri> (ChiCTR-IOR-15006673) on July 1, 2015, and the study methods and reporting were conducted in accordance with the CONSORT 2010 guidelines.</p></sec><sec id="S6"><title>Author Contributions</title><p>Conceived and designed the experiments: XM. Performed the experiments: PL, RS, YZhang, CL, BC, XL, JLi, XC, JK, JLou, WC, BZ, LZ, YY, YZhu, YG, and RZ. Analyzed the data: PL, RS, and BC. Contributed reagents/materials/analysis tools: PL and YZhang. Wrote the paper: PL, RS, and XM. Interpreted results and made many revisions of the manuscript: PL, RS, YZhang. Contributed to the revision of the manuscript and gave final approval for publication: PL, RS, and XM. All authors have reviewed and approved the manuscript as submitted.</p></sec><sec id="S7"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>The authors would like to thank all local MMT clinics staff for their important contributions to this study and thank all study subjects for their cooperation. The authors would also like to thank Dr. Michael R. Phillips for administrative and manuscript writing assistance. The opinions expressed herein reflect the collective views of the coauthors and do not necessarily represent the official position of the institute the authors are affiliated with.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This project is funded by China Medical Board (grant number: CMB09-991). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="book"><collab>CNNCC</collab>. <source>Annual Report on Drug Situation of China in 2014</source>. <publisher-loc>Beijing</publisher-loc>: <publisher-name>China National Narcotic Control Committee</publisher-name> (<year>2015</year>).</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="book"><collab>UNODC</collab>. <source>WORLD DRUG REPORT 2016</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>United Nations Office on Drugs and Crime</publisher-name> (<year>2016</year>).</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>B</given-names></name><name><surname>Okie</surname><given-names>S</given-names></name></person-group>
<article-title>China and HIV &#x02013; a window of opportunity</article-title>. <source>N Engl J Med</source> (<year>2007</year>) <volume>356</volume>(<issue>18</issue>):<fpage>1801</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMp078010</pub-id><pub-id pub-id-type="pmid">17476005</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Sullivan</surname><given-names>SG</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Rotheram-Borus</surname><given-names>MJ</given-names></name><name><surname>Detels</surname><given-names>R</given-names></name></person-group>. <article-title>Evolution of China&#x02019;s response to HIV/AIDS</article-title>. <source>Lancet</source> (<year>2007</year>) <volume>369</volume>(<issue>9562</issue>):<fpage>679</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(07)60315-8</pub-id><pub-id pub-id-type="pmid">17321313</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsch</surname><given-names>LA</given-names></name></person-group>. <article-title>The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis</article-title>. <source>Addiction</source> (<year>1998</year>) <volume>93</volume>(<issue>4</issue>):<fpage>515</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1046/j.1360-0443.1998.9345157.x</pub-id><pub-id pub-id-type="pmid">9684390</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>J</given-names></name><name><surname>Hall</surname><given-names>W</given-names></name><name><surname>Mattick</surname><given-names>RP</given-names></name></person-group>. <article-title>Role of maintenance treatment in opioid dependence</article-title>. <source>Lancet</source> (<year>1999</year>) <volume>353</volume>(<issue>9148</issue>):<fpage>221</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(98)05356-2</pub-id><pub-id pub-id-type="pmid">9923893</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLellan</surname><given-names>AT</given-names></name><name><surname>Arndt</surname><given-names>IO</given-names></name><name><surname>Metzger</surname><given-names>DS</given-names></name><name><surname>Woody</surname><given-names>GE</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>CP</given-names></name></person-group>. <article-title>The effects of psychosocial services in substance abuse treatment</article-title>. <source>JAMA</source> (<year>1993</year>) <volume>269</volume>(<issue>15</issue>):<fpage>1953</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1001/jama.1993.03500150065028</pub-id><pub-id pub-id-type="pmid">8385230</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>L</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Mi</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Rou</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Effectiveness of first eight methadone maintenance treatment clinics in China</article-title>. <source>AIDS</source> (<year>2007</year>) <volume>21</volume>(<issue>Suppl 8</issue>):<fpage>S103</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1097/01.aids.0000304704.71917.64</pub-id><pub-id pub-id-type="pmid">18172377</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Scaling up the national methadone maintenance treatment program in China: achievements and challenges</article-title>. <source>Int J Epidemiol</source> (<year>2010</year>) <volume>39</volume>(<issue>Suppl 2</issue>):<fpage>ii29</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="doi">10.1093/ije/dyq210</pub-id><pub-id pub-id-type="pmid">21113034</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Chow</surname><given-names>EP</given-names></name><name><surname>Zhuang</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Methadone maintenance treatment participant retention and behavioural effectiveness in China: a systematic review and meta-analysis</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>(<issue>7</issue>):<fpage>e68906</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0068906</pub-id><pub-id pub-id-type="pmid">23922668</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Lau</surname><given-names>JT</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Misconceptions predict dropout and poor adherence prospectively among newly admitted first-time methadone maintenance treatment clients in Guangzhou, China</article-title>. <source>Addiction</source> (<year>2012</year>) <volume>107</volume>(<issue>9</issue>):<fpage>1641</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1111/j.1360-0443.2012.03859.x</pub-id><pub-id pub-id-type="pmid">22360534</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marienfeld</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Schottenfeld</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Chawarski</surname><given-names>MC</given-names></name></person-group>. <article-title>Evaluation of an implementation of methadone maintenance treatment in China</article-title>. <source>Drug Alcohol Depend</source> (<year>2015</year>) <volume>157</volume>:<fpage>60</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.10.001</pub-id><pub-id pub-id-type="pmid">26601934</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="book"><collab>World Health Organization</collab>. <source>Global Hepatitis Report 2017</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name> (<year>2017</year>). Available from: <uri xlink:type="simple" xlink:href="http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/">http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/</uri> (Accessed: September 17, 2017).</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thrift</surname><given-names>AP</given-names></name><name><surname>El-Serag</surname><given-names>HB</given-names></name><name><surname>Kanwal</surname><given-names>F</given-names></name></person-group>. <article-title>Global epidemiology and burden of HCV infection and HCV-related disease</article-title>. <source>Nat Rev Gastroenterol Hepatol</source> (<year>2017</year>) <volume>14</volume>(<issue>2</issue>):<fpage>122</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1038/nrgastro.2016.176</pub-id><pub-id pub-id-type="pmid">27924080</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>CX</given-names></name><name><surname>Rou</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Baseline HCV antibody prevalence and risk factors among drug users in China&#x02019;s national methadone maintenance treatment program</article-title>. <source>PLoS One</source> (<year>2016</year>) <volume>11</volume>(<issue>2</issue>):<fpage>e0147922</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0147922</pub-id><pub-id pub-id-type="pmid">26906025</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>R</given-names></name></person-group>. <article-title>Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis</article-title>. <source>Public Health</source> (<year>2008</year>) <volume>122</volume>(<issue>10</issue>):<fpage>990</fpage>&#x02013;<lpage>1003</lpage>.<pub-id pub-id-type="doi">10.1016/j.puhe.2008.01.014</pub-id><pub-id pub-id-type="pmid">18486955</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China</article-title>. <source>Addiction</source> (<year>2015</year>) <volume>110</volume>(<issue>5</issue>):<fpage>796</fpage>&#x02013;<lpage>802</lpage>.<pub-id pub-id-type="doi">10.1111/add.12836</pub-id><pub-id pub-id-type="pmid">25529103</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amato</surname><given-names>L</given-names></name><name><surname>Minozzi</surname><given-names>S</given-names></name><name><surname>Davoli</surname><given-names>M</given-names></name><name><surname>Vecchi</surname><given-names>S</given-names></name></person-group>
<article-title>Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence</article-title>. <source>Cochrane Database Syst Rev</source> (<year>2011</year>) <volume>10</volume>:<fpage>CD004147</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD004147.pub4</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chawarski</surname><given-names>MC</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Schottenfeld</surname><given-names>RS</given-names></name></person-group>. <article-title>Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: a pilot randomized clinical trial</article-title>. <source>Drug Alcohol Depend</source> (<year>2011</year>) <volume>115</volume>(<issue>3</issue>):<fpage>237</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2010.09.024</pub-id><pub-id pub-id-type="pmid">21159452</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Lau</surname><given-names>JT</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>A randomized controlled trial to evaluate the relative efficacy of the addition of a psycho-social intervention to standard-of-care services in reducing attrition and improving attendance among first-time users of methadone maintenance treatment in China</article-title>. <source>AIDS Behav</source> (<year>2013</year>) <volume>17</volume>(<issue>6</issue>):<fpage>2002</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1007/s10461-012-0393-9</pub-id><pub-id pub-id-type="pmid">23413126</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>McLaughlin</surname><given-names>MM</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Ling</surname><given-names>L</given-names></name></person-group>. <article-title>Effectiveness of prize-based contingency management in a methadone maintenance program in China</article-title>. <source>Drug Alcohol Depend</source> (<year>2013</year>) <volume>133</volume>(<issue>1</issue>):<fpage>270</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2013.05.028</pub-id><pub-id pub-id-type="pmid">23831409</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Ling</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Efficacy of cognitive behavioral therapy on opiate use and retention in methadone maintenance treatment in china: a randomised trial</article-title>. <source>PLoS One</source> (<year>2015</year>) <volume>10</volume>(<issue>6</issue>):<fpage>e0127598</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0127598</pub-id><pub-id pub-id-type="pmid">26107818</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Peng</surname><given-names>CY</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Methadone maintenance treatment in China: perceived challenges from the perspectives of service providers and patients</article-title>. <source>J Public Health</source> (<year>2013</year>) <volume>35</volume>(<issue>2</issue>):<fpage>206</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1093/pubmed/fds079</pub-id><pub-id pub-id-type="pmid">22997278</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>McGoogan</surname><given-names>JM</given-names></name><name><surname>Rou</surname><given-names>K</given-names></name><name><surname>Bulterys</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name></person-group>. <article-title>Human resource development and capacity-building during China&#x02019;s rapid scale-up of methadone maintenance treatment services</article-title>. <source>Bull World Health Organ</source> (<year>2013</year>) <volume>91</volume>(<issue>2</issue>):<fpage>130</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.2471/BLT.12.108951</pub-id><pub-id pub-id-type="pmid">23554525</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Grimes</surname><given-names>DA</given-names></name></person-group>. <article-title>Sample size calculations in randomised trials: mandatory and mystical</article-title>. <source>Lancet</source> (<year>2005</year>) <volume>365</volume>(<issue>9467</issue>):<fpage>1348</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1016/s0140-6736(05)61034-3</pub-id><pub-id pub-id-type="pmid">15823387</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>YP</given-names></name><name><surname>Liu</surname><given-names>ZM</given-names></name><name><surname>Epstein</surname><given-names>DH</given-names></name><name><surname>Du</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name></person-group>. <article-title>A meta-analysis of retention in methadone maintenance by dose and dosing strategy</article-title>. <source>Am J Drug Alcohol Abuse</source> (<year>2009</year>) <volume>35</volume>(<issue>1</issue>):<fpage>28</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1080/00952990802342899</pub-id><pub-id pub-id-type="pmid">19152203</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>HM</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Chow</surname><given-names>EP</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Xian</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>YH</given-names></name><etal/></person-group>
<article-title>Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drug users in China: a systematic review and meta-analysis</article-title>. <source>BMJ Open</source> (<year>2015</year>) <volume>5</volume>(<issue>1</issue>):<fpage>e005997</fpage>.<pub-id pub-id-type="doi">10.1136/bmjopen-2014-005997</pub-id><pub-id pub-id-type="pmid">25573521</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>SG</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Rou</surname><given-names>K</given-names></name><name><surname>Pang</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Who uses methadone services in China? Monitoring the world&#x02019;s largest methadone programme</article-title>. <source>Addiction</source> (<year>2015</year>) <volume>110</volume>(<issue>Suppl 1</issue>):<fpage>29</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1111/add.12781</pub-id><pub-id pub-id-type="pmid">25533862</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>LE</given-names></name><name><surname>Metzger</surname><given-names>DS</given-names></name><name><surname>Fudala</surname><given-names>PJ</given-names></name><name><surname>Fiellin</surname><given-names>DA</given-names></name></person-group>. <article-title>Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users</article-title>. <source>Addiction</source> (<year>2005</year>) <volume>100</volume>(<issue>2</issue>):<fpage>150</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1111/j.1360-0443.2004.00963.x</pub-id><pub-id pub-id-type="pmid">15679744</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="book"><collab>World Health Organization</collab>. <source>Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name> (<year>2009</year>).</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pilling</surname><given-names>S</given-names></name><name><surname>Hesketh</surname><given-names>K</given-names></name><name><surname>Mitcheson</surname><given-names>L</given-names></name></person-group>
<source>Routes to Recovery: Psychosocial Interventions for Drug Misuse. A Framework and Toolkit for Implementing NICE-Recommended Treatment Interventions</source>. <publisher-loc>London</publisher-loc>: <publisher-name>British Psychological Association, National Treatment Agency</publisher-name> (<year>2010</year>).</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Detels</surname><given-names>R</given-names></name></person-group>
<article-title>Methadone treatment in primary care</article-title>. <source>Lancet HIV</source> (<year>2015</year>) <volume>2</volume>(<issue>10</issue>):<fpage>e408</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/s2352-3018(15)00134-4</pub-id><pub-id pub-id-type="pmid">26423645</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Rou</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Retention and its predictors among methadone maintenance treatment clients in China: a six-year cohort study</article-title>. <source>Drug Alcohol Depend</source> (<year>2014</year>) <volume>145</volume>:<fpage>87</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2014.09.776</pub-id><pub-id pub-id-type="pmid">25448082</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Hao</surname><given-names>C</given-names></name><name><surname>Jiao</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Club drugs and alcohol abuse predicted dropout and poor adherence among methadone maintenance treatment patients in Guangzhou, China</article-title>. <source>AIDS Care</source> (<year>2017</year>) <volume>29</volume>(<issue>4</issue>):<fpage>458</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1080/09540121.2016.1259452</pub-id><pub-id pub-id-type="pmid">27903083</pub-id></mixed-citation></ref></ref-list></back></article>